Abstract
The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover, scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate the role of PDE5 inhibitors in the regulation of the sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.
Keywords: Spermatozoa, testis, epididymis, phosphodiesterase, prostate, seminal vesicles, PDE5 inhibitors.
Current Pharmaceutical Design
Title:The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Volume: 27 Issue: 23
Author(s): Nikolaos Sofikitis*, Aris Kaltsas, Fotios Dimitriadis, Jens Rassweiler, Nikolaos Grivas, Athanasios Zachariou, Apostolos Kaponis, Panagiota Tsounapi, Napoleon Paterakis, Andreas Karagiannis, Sotirios Skouros, Ioannis Giannakis, Ioannis Champilomatis, Minas Paschopoulos, Diamantis Daphnis, Ioannis Giakoumakis, Melinda R.Gabales, Jo Ben M. Chua, Pedro L. Lantin III, Charalampos Mamoulakis and Atsushi Takenaka
Affiliation:
- Department of Urology, Ioannina University School of Medicine, Ioannina,Greece
Keywords: Spermatozoa, testis, epididymis, phosphodiesterase, prostate, seminal vesicles, PDE5 inhibitors.
Abstract: The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover, scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate the role of PDE5 inhibitors in the regulation of the sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.
Export Options
About this article
Cite this article as:
Sofikitis Nikolaos *, Kaltsas Aris , Dimitriadis Fotios , Rassweiler Jens , Grivas Nikolaos , Zachariou Athanasios , Kaponis Apostolos , Tsounapi Panagiota , Paterakis Napoleon , Karagiannis Andreas , Skouros Sotirios , Giannakis Ioannis , Champilomatis Ioannis , Paschopoulos Minas , Daphnis Diamantis , Giakoumakis Ioannis , R.Gabales Melinda , M. Chua Ben Jo , Lantin III L. Pedro, Mamoulakis Charalampos and Takenaka Atsushi , The Effect of PDE5 Inhibitors on the Male Reproductive Tract, Current Pharmaceutical Design 2021; 27 (23) . https://dx.doi.org/10.2174/1381612826666200226121510
DOI https://dx.doi.org/10.2174/1381612826666200226121510 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update
Recent Patents on Cardiovascular Drug Discovery Homocysteine, Cardiovascular Inflammation, and Myocardial Remodeling
Cardiovascular & Hematological Disorders-Drug Targets Biomarkers of Aging with Prognostic and Predictive Value in Non-Oncological Diseases
Current Medicinal Chemistry Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Current Drug Targets Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences Cardiovascular Effects of the Phytoestrogen Genistein
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Global Safety of Coxibs and NSAIDs
Current Topics in Medicinal Chemistry Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry Role, Function and Therapeutic Potential of microRNAs in Vascular Aging
Current Vascular Pharmacology Antioxidant Treatment and Endothelial Dysfunction: Is it Time for Flavonoids?
Recent Patents on Cardiovascular Drug Discovery Family B G Protein-coupled Receptors and their Ligands: From Structure to Function
Current Medicinal Chemistry The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Estimating Alzheimer’s Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia
Current Alzheimer Research Therapeutic Prospects of PPARs in Psychiatric Disorders: A Comprehensive Review
Current Drug Targets